Allon receives Qualifying Therapeutic Discovery Project grants for drug development from U.S. government
08-Nov-2010
- Canada
The grants awarded to the Company will help fund development of Allon’s clinical-stage neuroprotective drug candidate davunetide as a treatment for progressive supranuclear palsy (PSP) and preclinical-stage drug candidate AL-309 as a treatment for peripheral neuropathy.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
Syngenta invests in Avidex
Go to page
Deepak_Acharya
Go to page
EPLAN Software & Service GmbH & Co. KG - Monheim am Rhein, Germany
Go to page
Mitsui Chemicals to Consolidate its Three Agrochemicals Subsidiaries
Go to page
Cyprotex receives dual boost for research development
Go to page
New mitochondrial control mechanism discovered
Go to page
Nanobody candidate selected by Boehringer Ingelheim for development
Go to page
Growing European Drug Developer Awards $1.5 Million Study to eResearchTechnology - Commitment Continues Global Trend Toward Thorough Phase I ECG Studies
Go to page
Amgen Completes Acquisition of Abgenix - Acquisition Provides Amgen with Full Ownership of Panitumumab and Eliminates a Denosumab Royalty
Go to page
Therapure Biopharma Inc. - Mississauga, Canada
Go to page